Accéder au contenu
MilliporeSigma

MSQC9

SILuMAb Infliximab Stable-Isotope Labeled Monoclonal Antibody

recombinant, expressed in CHO cells

Synonyme(s) :

Mass spectrometry standard, Infliximab, SIL Infliximab, Stable isotope labelled Infliximab

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

Changer de vue

A propos de cet article

NACRES:
NA.41
UNSPSC Code:
12352200
Clone:
-
Species reactivity:
-
Application:
Citations:
-
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider


recombinant

expressed in CHO cells

Quality Level

antibody product type

primary antibodies

assay

≥90% (SDS-PAGE)

packaging

vial of 100 μg

shipped in

wet ice

storage temp.

−20°C

General description

SILuMAb Infliximab Stable-Isotope Labeled Monoclonal Antibody (MSQC9) is a recombinant, stable isotope-labeled, monoclonal antibody which incorporates [13C6, 15N4]-Arginine and [13C6, 15N2]-Lysine. Expressed in CHO cells, it is designed to be used as an internal standard for the quantitative mass spectrometry analysis of Infliximab in human serum. Infliximab is a chimeric monoclonal antibody biologic drug that works against tumor necrosis factor alpha (TNF-a) and is used to treat autoimmune diseases.
Infliximab has been approved for the treatment of Crohn′s disease, ulcerative colitis, psoriasis, psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis. SILuMAb Infliximab Stable-Isotope Labeled Monoclonal Antibody is for R&D use only. Not for drug, household, or other uses.

Physical form

Each vial of SILuMab Infliximab Stable-Isotope Labeled Monoclonal Antibody contains the labeled antibody in a lyophilized form containing phosphate buffered saline.

Preparation Note

Produced utilizing enriched media containing stable isotope labeled amino acids are 13C6, 15N4-labeled Arginine and 13C6, 15N2-labeled Lysine.
SILuMab Infliximab Stable-Isotope Labeled Monoclonal Antibody is designed to be used as a internal standard for analysis of Infliximab in human serum.
SILuMab Infliximab recovery is maximized when 0.1% formic acid is used for reconstitution of the lyophilized product.Reconstitution with other solvents may reduce recovery. Do not freeze after reconstitution.

  • Briefly centrifuge the vial at ~10,000 × g to collect the product at the bottom of the vial.
  • Add 500 μL of ultrapure water containing 0.1% formic acid to the vial.
  • Mix the contents by gently inverting the vial a minimum of 5 times.
  • Allow the vial to stand at room temperature for at least 15 minutes and repeat mixing by inversion.

Analysis Note

Quantitative
MRM settings provided (xls)

Legal Information

This product is licensed under U.S. Patent No. 7,396,688 and foreign counterparts from E. I. du Pont de Nemours and Company. The purchase of this product conveys to the buyer the nontransferable right to use the purchased amount of the product for research and development only, including services for a third party for consideration. The buyer cannot sell or otherwise transfer this product, its components or materials made using this product or its components to a third party. Information about licenses for excluded uses is available from: E. I. du Pont de Nemours and Company; Attn: Associate Director, Commercial Development; DuPont Experimental Station E268; 200 Powdermill Rd.; Wilmington, DE 19803; 1-877-881-9787 (voice), 1-302-695-1437 (fax), licensing@dupont.com.
SILu is a trademark of Sigma-Aldrich Co. LLC


Still not finding the right product?

Essayez notre Outil de sélection de produits pour affiner vos choix.


Classe de stockage

13 - Non Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents


Articles

Infliximab, a chimeric monoclonal antibody, is used to treat rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and other autoimmune diseases.

Contenu apparenté





Numéro d'article de commerce international

RéférenceGTIN
MSQC9-100UG04061832012599